Abstract
Pathogenic heterozygous variants in DHX16 have been recently identified in association with a variety of clinical features, including neuromuscular disease, sensorineural hearing loss, ocular anomalies, and other phenotypes. All DHX16 disease-causing variants previously reported in affected individuals are missense in nature, nearly all of which were found to be de novo. Here we report on a patient with neuromuscular disease, hearing loss, retinal degeneration, and previously unreported phenotypic features including mitochondrial deficiency and primary ovarian insufficiency, in whom a novel de novo likely pathogenic variant in DHX16 NM_003587.4:c.2033A > G (p.Glu678Gly) was identified. Furthermore, we conducted an in-depth literature review of DHX16's role in disease and utilized high-performing in silico prediction algorithms to compare and contrast the predicted effects of all reported disease-associated DHX16 variants on protein structure and function.
Original language | English (US) |
---|---|
Pages (from-to) | 53-58 |
Number of pages | 6 |
Journal | American Journal of Medical Genetics, Part A |
Volume | 194 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2024 |
Funding
Dr. Rao has received grants from NS Pharma, RegenxBio, Alexion, and Sarepta and nonfinancial support from Ann and Robert H. Lurie Children's Hospital for conduct of clinical trials. Dr. Rao has also received personal fees from Biogen, Avexis/Novartis, Capricor, NSPharma, Regenxbio, Genentech‐Roche, Scholar Rock, PTC Therapeutics, Sarepta Therapeutics, France Foundation, and MDA outside the submitted work.
Keywords
- DHX16
- NMOAS
- hearing loss
- neuromuscular disease
- primary ovarian insufficiency
- retinal degeneration
ASJC Scopus subject areas
- Genetics(clinical)
- Genetics